BioInvent: BioInvent’s Rights Issue Oversubscribed and a Prospectus Supplement is Published

Regulatory News:

BioInvent (STO:BINV)

Allotment As previously announced, the rights issue in BioInvent of MSEK 48.9, with preferential rights for the company’s shareholders, has been oversubscribed. The subscription period ended on 11 April 2014. Approx. 95 per cent of the shares offered have been subscribed for with subscription rights and 5 per cent of the shares offered have been allocated to persons who subscribed for shares without subscription rights. In total, notifications to subscribe for shares without subscriptions rights have been received corresponding to 101 per cent of the shares offered. Hence, the rights issue guarantee undertakings have not been made use of.

Allocation of shares that were subscribed for without subscription rights has been made in accordance with the principles outlined in the prospectus that has been prepared in connection with the rights issue and that was published on 25 March 2014. Notification regarding such allocation will within short be sent to those who have been allocated shares

As previously announced, BioInvent has at the same time carried out a directed new share issue of MSEK 15.0 to Henrik Rhenman through Rhenman Healthcare Equity L/S and Peter Thelin through East Bay AB. The directed new share issue has been subscribed for at a price equal to that in the rights issue, SEK 2.30 per share.

Through the rights issue and the directed new share issue, BioInvent receives MSEK 63.9 before deduction of transaction costs. The share capital will increase by approx. MSEK 2.2 from approx. MSEK 6.8 to approx. MSEK 9.0 and the number of shares will increase by 27,775,401 from 85,014,649 shares to 112,790,050 shares when the new share issues have been registered with the Swedish Companies Registration Office. Trading in the new shares on NASDAQ OMX Stockholm is expected to commence around week 21, 2014.

Prospectus supplement concerning BioInvent’s rights issue is published In accordance with the press release 15 April, 2014, the Board of Directors has prepared a prospectus supplement concerning the rights issue with preferential right for existing shareholders, which has been registered by the Swedish Financial Supervisory Authority (SFSA). The prospectus supplement is available in Swedish at BioInvent’s website, www.bioinvent.com, and on Erik Penser Bankaktiebolag’s website, www.penser.se.

The prospectus supplement can also be received free of charge from BioInvent International AB, Ideon Science Park, 223 70 Lund, telephone +4646-286 85 50 or from Erik Penser Bankaktiebolag email; emission@penser.se or by post on Erik Penser Bankaktiebolag, Emissionsavdelningen/BioInvent, Box 7405, SE-103 91 Stockholm, Sweden.

Advisors Erik Penser Bankaktiebolag is acting as financial advisor and Mannheimer Swartling Advokatbyrå AB is acting as legal advisor to BioInvent in connection to the new share issues.

-- END –

To the editors:

About BioInvent

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer.

The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody library n-CoDeR® are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Les Laboratoires Servier and Mitsubishi Tanabe Pharma. More information is available at www.bioinvent.com.

BioInvent International AB (publ) Co. reg. No. 556537-7263 Visiting address: Sölvegatan 41 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 info@bioinvent.com www.bioinvent.com

Important information The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in BioInvent. Any invitation to the persons concerned to subscribe for shares in BioInvent was only made through the prospectus that BioInvent published on 25 March 2014.

This press release may not be published or distributed, directly or indirectly in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand or South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or would require such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares will be registered under the United States Securities Act of 1933 ("Securities Act”) or securities legislation in any other state or other jurisdiction in the United States and may not be offered, subscribed, sold or transferred, directly or indirectly within the United States, other than pursuant to an exemption from the registration requirements of the Securities Act and in accordance with securities laws in relevant state or other jurisdiction in the United States.

This press release may contain forward-looking statements which reflect BioInvent's current view on future events and financial and operational development. Words such as "intend”, "expect”, "anticipate”, "may”, "believe”, "plan”, "estimate” and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the real outcome could differ materially from the forward-looking statements.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.40 a.m. CET, on 17 April, 2014.

This information was brought to you by Cision http://news.cision.com